SOUTH SAN FRANCISCO, Calif., Dec. 16, 2020 /PRNewswire/ --Neuron23Inc., an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced its launch backed by a combined $113.5 million Series A and B financing. The funding was comprised of $33.5 million Series A financing from Westlake Village BioPartners and Kleiner Perkins, and $80 million Series B financing led by Redmile Group. Additional Series B investors included Westlake Village BioPartners, Kleiner Perkins, Cowen Healthcare Investments, Acorn Bioventures, HBM Partners, Perceptive Advisors, and Surveyor Capital (a Citadel company). Neuron23 was founded through an innovative partnership with German biotechnology company, Origenis GmbH.
Proceeds from the financing will be used to accelerate the development of Neuron23's pipeline and expand its state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms for identifying therapeutics for devastating neurodegenerative diseases including Parkinson's disease, neuroinflammatory diseases such as multiple sclerosis, and systemic autoimmune and inflammatory diseases. Specifically, the round will allow the company to advance two-to-three existing development candidates into the clinic in the next 24 months, and to bolster its platform to identify genetic signatures of patients most likely to respond to the development candidates. Within each program, the potential exists to address multiple central nervous system (CNS) and systemic diseases, creating "pipeline within a product" opportunities. Proceeds from the financing will also support talent recruitment, technology development, and intellectual property (IP) expansion and protection.
"We are pleased to have such strong support from this syndicate of blue-chip investors who recognize our potential to build a new type of precision medicine company," said Nancy Stagliano, PhD, CEO and Board Chair, Neuron23. "Neuron23's approach can revolutionize how we treat genetically defined neurological and inflammatory diseases, thus significantly improving patients' lives. Our team of accomplished entrepreneurs, scientists, and clinicians, with significant experience in drug discovery and development, is poised to harness the latest technologies in AI, human genetics, and medicinal chemistry to streamline the delivery of the right medicines to both genetically defined patients and the broader group."
Neuron23 is advancing multiple therapeutics addressing genetically validated targets, with lead programs against leucine-rich repeat kinase 2 (LRRK2), a gene associated with Parkinson's disease and systemic inflammatory diseases, and tyrosine kinase 2 (TYK2), a JAK family protein that plays a role in pathological immune signaling. The prioritization of LRRK2 and TYK2 allows the company to spotlight its foundational strengths in chemistry, biology, human genetics, and AI.
Beth Seidenberg, MD, co-founding managing director of Westlake Village BioPartners and a partner at Kleiner Perkins, led the Series A round and participated in the Series B round.
"Neuron23 has tremendous potential to usher in the next step-change in treating genetically defined neurological and immunological diseases, and the caliber of the investors in our syndicate speaks to the excitement around Neuron23 and its future," Dr. Seidenberg said. "Dr. Stagliano brings significant expertise in neuroscience and a proven ability building high-performing companies, having previously served as CEO of True North Therapeutics, iPierian, and CytomX Therapeutics. With Dr. Stagliano at the helm, we are well positioned for a number of financing scenarios in the future, including additional private capital, accessing the public markets, or partnering with Big Pharma."
Neuron23 has been working in stealth mode since its founding in October 2018 by neurogeneticist and Chief Business Officer Adam Knight, PhD, along with Origenis GmbH, and Kleiner Perkins.
"Our partnership with Origenis gives us significant competitive advantages over traditional drug discovery approaches, including high throughput capabilities to identify scores of potent, selective, and brain-penetrant molecules for each target," said Dr. Knight.
In connection with the Series A and B rounds, Beth Seidenberg, Amrit Nagpal (Redmile Group), Kevin Raidy (Cowen Healthcare Investments), Michael Almstetter (Origenis), and Nancy Stagliano serve on the Board of Directors.
Westlake Village BioPartners recently launched two funds totaling $500 million and launched a new biopharma company, ACELYRIN. Westlake's investment in the Series B round for Neuron23 came from its Opportunity 1 fund, one of the new funds launched and designed to invest additional capital into companies they incubated that show promise. "We are doubling down on Neuron23," added Dr. Seidenberg.
Neuron23Inc. is an early stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 leverages recent advances in human genetics, combined with their state-of-the-art artificial intelligence (AI)-enabled drug discovery and biomarker platforms, to advance therapeutics for devastating diseases. The Company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA, and Munich, Germany. For more information, please visit http://www.neuron23.com.
About Origenis GmbH
Origenis GmbH is a privately held German biopharmaceutical company developing brain-penetrating highly selective small molecule medicines and diagnostics for a variety of neurodegenerative and neuroinflammatory diseases. Origenis leverages its unique capabilities in drug design, compound synthesis, and characterization to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis' approach has been validated by multiple partners resulting in a significant IP and R&D portfolio that ensures strong patent protection. For more information, visitwww.origenis.com.
About Westlake Village BioPartners
Westlake Village BioPartners is a Los Angeles area-based venture capital firm focused on incubating and building life sciences companies with entrepreneurs who have the potential to bring transformative therapies and technologies to patients. Westlake manages more early stage venture capital solely from the greater Los Angeles area than any other firm. The Westlake model is built on the founding team's unique experience in successfully identifying and developing breakthrough therapies and building organizations, based on their extensive R&D experience. For more information, please visitwww.westlakebio.com.
- Bionano Genomics Announces ESHG Lineup Featuring 11 Customer Presentations of OGM Data Spanning Three Major Clinical Research Areas of Application... - August 31st, 2021
- Investing in the Power of Pathology and Genomics - Tufts Now - August 31st, 2021
- Humans are more than just a bag of genes - Commentary Box Sports - August 31st, 2021
- What Is the Most Important Scientific Development of the Last 50 Years? - Gizmodo Australia - August 31st, 2021
- 6 Greatest Breakthroughs in Agriculture that Changed the World - Krishi Jagran - August 31st, 2021
- Animal Expert Shares 5 Things That Will Help Your Dog Live a Longer, Healthier Life - ScienceAlert - August 31st, 2021
- Roman Catholics of Goa, Mangalore have early lineages of Brahmin community: Study - NewsMeter - August 31st, 2021
- The Poop About Your Gut Health and Personalized Nutrition - WIRED - August 31st, 2021
- Latest Research Strengthens Link Between Genetics and Suicidal Behaviors - University of Utah Health Care - July 21st, 2021
- Mixed-ancestry genetic research shows a bit of Native American DNA could reduce risk of Alzheimer's disease - The Conversation US - July 21st, 2021
- COVID-19 Roundup: The Unvaccinated Fuel Hospitalizations; Genetic Link to Severe Illness; and Children's Infection Rate - Baptist Health South Florida - July 21st, 2021
- Luck of the draw: How the random results of the genetic lottery can influence a host of your life's outcomes - Milwaukee Journal Sentinel - July 21st, 2021
- Kafer: The scary, promising and not too distant future of gene editing technology - The Denver Post - July 21st, 2021
- MUST READ OF THE WEEK: THE GENOME ODYSSEY BY DR EUAN ANGUS ASHLEY - Blackpool Gazette - July 21st, 2021
- Vence Bonham to be appointed acting NHGRI deputy director - National Human Genome Research Institute - June 6th, 2021
- UMaine researchers: Culture drives human evolution more than genetics - UMaine News - University of Maine - University of Maine - June 6th, 2021
- Myriad Genetics Recalibrates Breast Cancer PRS for All Ancestries in Anticipation of Broader Launch - Precision Oncology News - June 6th, 2021
- Amgen To Present At The Goldman Sachs 42nd Annual Global Healthcare Conference - Yahoo Finance - June 6th, 2021
- Unprecedented Data Sharing Drives New Rare Disease Diagnoses Just Tip of the Iceberg - SciTechDaily - June 6th, 2021
- New Approach to DNA Research Could Be Key to Solving Mysteries of Deadly Diseases - University of Virginia - June 6th, 2021
- Critics of Alberta's new rules for supervised consumption sites say they will curb access for vulnerable clients - The Globe and Mail - June 6th, 2021
- The 'Wondrous Map': Charting of the Human Genome, 20 Years Later - Medscape - December 16th, 2020
- Leading UK Core Labs Expand Investment in PacBio Sequencing Systems to Power Life Science Research with HiFi Reads - GlobeNewswire - December 16th, 2020
- Unique genetic factors and ancestry, along with lifestyle, influence skin cancer risk - Kaiser Permanente Division of Research - December 16th, 2020
- NIH's All of Us Research Program returns first genetic results to participants - National Institutes of Health - December 16th, 2020
- ONLINE: Wednesday Nite at the Lab - Isthmus - December 16th, 2020
- Researchers identify the origin of a deadly brain cancer - McGill Newsroom - December 16th, 2020
- Meet the MBA Class of 2022: Christopher Connolly, University of Michigan (Ross) - Poets&Quants - December 16th, 2020
- Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia... - December 16th, 2020
- Differences, Demonization, and DNA | Opinion - Harvard Crimson - November 17th, 2020
- Weekend reads: Inside one of Hollywood's most famous hotels amid the Covid-19 epidemic - The Daily Briefing - November 7th, 2020
- First Line Sequencing Seen as a Win for Both Parents and Doctors of Infants in ICU - Clinical OMICs News - November 7th, 2020
- Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano's Optical Genome Mapping Technology Can Diagnose... - November 7th, 2020
- Experiencing happiness likely contributed to the dramatic growth and complexity of the human brain - Genetic Literacy Project - November 7th, 2020
- NIH researchers identify gene in mice that controls food cravings, desire to exercise - National Institutes of Health - November 7th, 2020
- Amgen To Present At The 29th Annual Credit Suisse Healthcare Conference - WFMZ Allentown - November 7th, 2020
- Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail's CEO - GlobeNewswire - November 7th, 2020
- Focusing on the Future of Genetic Testing in Oncology - OncLive - October 10th, 2020
- ASHG 2020 Virtual Meeting to Showcase Innovative Research in Human Genetics - BioSpace - October 10th, 2020
- Evenings with Genetics discusses connection between cancer and genetics - Baylor College of Medicine News - October 10th, 2020
- Promoting global collaboration for brain health research - The BMJ - October 10th, 2020
- SKYMINT BRANDS -- Formerly Green Peak Innovations -- Joins Forces With DNA Genetics To Bring The World's Most Globally Awarded Flower Strains To... - October 10th, 2020
- U of T's Medicine by Design invests $1 million to advance new ideas in regenerative medicine - News@UofT - October 10th, 2020
- DCeased Proves Why Superboy Is the DC Universe's Gohan | CBR - CBR - Comic Book Resources - October 10th, 2020
- COVID-19 Shines Light on Disparities in Care for Patients With Cancer - OncLive - October 10th, 2020
- Genetic Study Uncovers Mutation Associated with Fibromuscular Dysplasia - University of Michigan Health System News - September 22nd, 2020
- Biopharm America: Of 'psychotic' behavior and term sheets in online dealmaking's brave new world - BioWorld Online - September 22nd, 2020
- 'It's all in the brain': The science behind stuttering - Genetic Literacy Project - September 22nd, 2020
- Jumpcode Genomics Exits Stealth Mode, Unveils Technology that Addresses the 'Needle in the Haystack' Problem of Molecular Biology - Bio-IT World - September 22nd, 2020
- Sex is real - aeon.co - September 22nd, 2020
- Coronavirus mutations: what we've learned so far - The Conversation UK - September 22nd, 2020
- Illumina to buy Jeff Bezos-backed cancer testing firm Grail in $8 billion deal - Metro US - September 22nd, 2020
- NeuBase Therapeutic's CEO, Dietrich A. Stephan, Ph.D., to Present at Tribe Public's Presentation and Q&A Webinar Event on August 26, 2020 - BioSpace - August 26th, 2020
- Canada Foundation for Innovation invests $9.3M in McGill highly-specialized research infrastructures - Science Business - August 26th, 2020
- Closing Gaps in Care: COVID-19 in Patients With Cancer Bring Health Inequities to the Surface - Targeted Oncology - August 26th, 2020
- Gains for humans, cows and the environment in breeding a socially acceptable cow - Dairy News Australia - August 26th, 2020
- Meet the Researcher: Xiaomei Cong, School of Nursing - UConn Today - August 26th, 2020
- Returning Weldon to head up full-time lab - Royal Gazette - August 26th, 2020
- Stanford alum investigates link between genomics and COVID-19 vulnerability - The Stanford Daily - August 16th, 2020
- The Secret to a Long, Healthy Life Is in the Genes of the Oldest Humans Alive - Singularity Hub - August 16th, 2020
- Humans have had mystery DNA for 300,000 yearsand now we might finally know what it is - SYFY WIRE - August 16th, 2020
- BUILDING THE NATION WITH QUALITY EDUCATION - The Star Online - August 16th, 2020
- 'Precision nutrition': Are hyper-individualized diets the future of eating? - The Week Magazine - August 16th, 2020
- Dairy culture on the Eurasian Steppe - Harvard Magazine - August 16th, 2020
- Race Is Real, But It's Not Genetic - Discover Magazine - June 30th, 2020
- Human Genetics Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast- 2025 - Cole... - June 30th, 2020
- Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer -... - June 30th, 2020
- deCODE Genetics: Loss of Function Variant in FLT3 Strongly Increases the Risk of Autoimmune Thyroid Disease and Other Autoimmune Diseases - Yahoo... - June 30th, 2020
- Scientists and Societies Decry Trump Executive Order on Immigration Visas - Genetic Engineering & Biotechnology News - June 30th, 2020
- Unpicking the complexity of DNA mutations - Cambridge Network - June 30th, 2020
- And finally... Where there's muck, there's brass - Scottish Construction Now - June 30th, 2020
- Cause of Common Autoinflammatory Disease May Have Protected Ancestors From Plague - Technology Networks - June 30th, 2020
- After the MadnessPandemic Silver Linings in Bioscience - NEO.LIFE - June 5th, 2020
- First studies of human genetic variation released by gnomAD Consortium - Drug Target Review - June 5th, 2020
- Rocket, arugula, rucola: how genetics determines the health benefits and whether you like this leafy green - The Conversation UK - June 5th, 2020
- Intravacc Partners with Wageningen Bioveterinary Research and Utrecht University - Contract Pharma - June 5th, 2020
- 'Lady in the well' sheds light on ancient human population movements - Reuters - June 5th, 2020
- COVID-19 testing capacity increased to 1,000 daily for UTRGV - KGBT-TV - June 5th, 2020
- COVID-19 study looks at genetics of healthy people who develop severe illness - Washington University School of Medicine in St. Louis - May 22nd, 2020
- Evolution of practice - Gazette - May 22nd, 2020